Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells

Fig. 5

WZ35 and cisplatin combination inhibited TrxR1 activity in gastric cancer cells. (a) Molecular docking of WZ35 with TrxR1 protein was carried out with the docking software. (b-c) TrxR1 activity was measured in SGC-7901 or BGC-823 cells after treated with WZ35 or cisplatin. (d) SGC-7901 or BGC-823 cells were treated with WZ35 or cisplatin alone or their combination at the indicated doses. At 2 h after treatment, TrxR1 activity was measured by the endpoint insulin reduction assay. (e) SGC-7901 or BGC-823 cells were treated with WZ35 or cisplatin alone or their combination at the indicated doses. At 12 h after treatment, the TrxR1 expression was determined by western blot. Data represent similar results from three independent experiments. (* p < 0.05, ** p < 0.01)

Back to article page